CHMP Gives Nod to Expanded Use of J&Js Rybrevant & AZNs Imfinzi
The CHMP recommends approval for JNJs subcutaneous formulation of Rybrevant in NSCLC and AstraZenecas Imfinzi in limited-stage small-cell lung cancer.…
83,316$
-0,12%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Total Voting Rights
3 February 2025
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…
Imfinzi recommended for EU approval for LS-SCLC
3 February 2025
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung…
AstraZeneca ditches £450m investment in UK plant
The drugs giant blames "protracted" talks with the government as well as differences over funding.…